Volume 12 Issue 283
Published - 14:00 UTC 08:00 EST 24-Oct-2010 
Next Update - 14:00 UC 08:00 EST 25-Oct-2010

Editor: Susan K. Boyer, RN
Vidyya.
All rights reserved.




  

 




Sorpion has welcome sting for heart bypass patients

(24 October 2010: VIDYYA MEDICAL NEWS SERVICE) -- A toxin found in the venom of the Central American bark scorpion (Centruroides margaritatus) could hold the key to reducing heart bypass failures, according to research from the University of Leeds.

The study, published online in Cardiovascular Research, reports that one of the scorpion's toxins, margatoxin, is at least 100 times more potent at preventing neointimal hyperplasia - the most comon cause of bypass graft failure - than any other known compound.

Neointimal hyperplasia is the blood vessel's response to injury. It triggers the growth of new cells, causing chronic obstruction on the inside of the vessel.

When a vein is grafted onto the heart during a bypass procedure, the injury response kicks in as the vein tries to adapt to the new environment and different circulatory pressures. Whilst the growth of new cells helps to strengthen the vein, the internal cell growth restricts blood flow and ultimately causes the graft to fail.

The potency of the margatoxin in suppressing the injury response mechanism took the team by surprise, says lead author Professor Beech from the University's Faculty of Biological Sciences. "It's staggeringly potent. We're talking about needing very few molecules in order to obtain an effect."

The toxin works by inhibiting the activity of a specific potassium ion channel - a pore in the cell membrane that opens and closes in response to electrical signals and indirectly enhances delivery of a intracellular messenger, the calcium ion.

"We knew from experimental research in immunology that the ion channel Kv1.3 is involved in activating immune system responses and that it's linked with chronic inflammation problems in the immune system, such as those you see with multiple sclerosis," says Professor Beech. "Since our own studies had identified Kv1.3's presence in injured blood vessels, which are also often complicated by chronic inflammation, we wanted to see if the same immune system blockers would inhibit neointimal hyperplasia."

"There were a number of good blockers of this ion channel available to screen. Several compounds are developed from plants, and one comes from scorpion venom," he says, "but margatoxin was the most potent of all these compounds by a significant margin."

Professor Beech says margatoxin would probably be unsuitable as a drug that could be swallowed, inhaled or injected, but it could potentially be taken forward as a spray-on treatment to the vein itself once it's been removed and is waiting to be grafted onto the heart.

Potent suppression of vascular smooth muscle cell migration and human neointimal hyperplasia by KV1.3 channel blockers Alex Cheong; Jing Li; Piruthivi Sukumar; Bhaskar Kumar; Fanning Zeng; Kirsten Riches; Christopher Munsch; Ian C. Wood; Karen E. Porter; David J. Beech Cardiovascular Research 2010; doi: 10.1093/cvr/cvq305.

Return to Vidyya Medical News Service for 24 October 2010

© Vidyya. All rights reserved.

Information appearing on the Vidyya Medical News Service is not intended as a substitute for professional medical care. Seek professional medical help and follow your health care provider's advice.

Our website hosts Google sponsored ads and links. We do not control Google ads content and our editorial content is free of any commercial influence.

Interested in subscribing to our daily e-mail newsletter? Send an email to Vidyya@vidyya.com with the word subscribe in the subject field.